198 related articles for article (PubMed ID: 34806402)
21. Therapeutic strategies for Huntington's disease.
Estevez-Fraga C; Flower MD; Tabrizi SJ
Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
[TBL] [Abstract][Full Text] [Related]
22. Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
[TBL] [Abstract][Full Text] [Related]
23. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
[TBL] [Abstract][Full Text] [Related]
24. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
[TBL] [Abstract][Full Text] [Related]
25. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
[TBL] [Abstract][Full Text] [Related]
26. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo.
Huang B; Schiefer J; Sass C; Landwehrmeyer GB; Kosinski CM; Kochanek S
Hum Gene Ther; 2007 Apr; 18(4):303-11. PubMed ID: 17472569
[TBL] [Abstract][Full Text] [Related]
27. Widespread and sustained target engagement in Huntington's disease minipigs upon intrastriatal microRNA-based gene therapy.
Vallès A; Evers MM; Stam A; Sogorb-Gonzalez M; Brouwers C; Vendrell-Tornero C; Acar-Broekmans S; Paerels L; Klima J; Bohuslavova B; Pintauro R; Fodale V; Bresciani A; Liscak R; Urgosik D; Starek Z; Crha M; Blits B; Petry H; Ellederova Z; Motlik J; van Deventer S; Konstantinova P
Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827977
[TBL] [Abstract][Full Text] [Related]
28. Gene Therapy for Huntington's Disease Using Targeted Endonucleases.
Dabrowska M; Olejniczak M
Methods Mol Biol; 2020; 2056():269-284. PubMed ID: 31586354
[TBL] [Abstract][Full Text] [Related]
29. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
31. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
[TBL] [Abstract][Full Text] [Related]
32. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
Garriga-Canut M; Agustín-Pavón C; Herrmann F; Sánchez A; Dierssen M; Fillat C; Isalan M
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3136-45. PubMed ID: 23054839
[TBL] [Abstract][Full Text] [Related]
33. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
Song H; Li H; Guo S; Pan Y; Fu Y; Zhou Z; Li Z; Wen X; Sun X; He B; Gu H; Zhao Q; Wang C; An P; Luo S; Hu Y; Xie X; Lu B
Brain; 2018 Jun; 141(6):1782-1798. PubMed ID: 29608652
[TBL] [Abstract][Full Text] [Related]
34. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.
Träger U; Andre R; Lahiri N; Magnusson-Lind A; Weiss A; Grueninger S; McKinnon C; Sirinathsinghji E; Kahlon S; Pfister EL; Moser R; Hummerich H; Antoniou M; Bates GP; Luthi-Carter R; Lowdell MW; Björkqvist M; Ostroff GR; Aronin N; Tabrizi SJ
Brain; 2014 Mar; 137(Pt 3):819-33. PubMed ID: 24459107
[TBL] [Abstract][Full Text] [Related]
35. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.
Olson SD; Kambal A; Pollock K; Mitchell GM; Stewart H; Kalomoiris S; Cary W; Nacey C; Pepper K; Nolta JA
Mol Cell Neurosci; 2012 Mar; 49(3):271-81. PubMed ID: 22198539
[TBL] [Abstract][Full Text] [Related]
36. The use of artificial microRNA technology to control gene expression in Arabidopsis thaliana.
Eamens AL; McHale M; Waterhouse PM
Methods Mol Biol; 2014; 1062():211-24. PubMed ID: 24057368
[TBL] [Abstract][Full Text] [Related]
37. Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
Dufour BD; Smith CA; Clark RL; Walker TR; McBride JL
Mol Ther; 2014 Apr; 22(4):797-810. PubMed ID: 24390280
[TBL] [Abstract][Full Text] [Related]
38. Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington's disease mice.
Mégret L; Nair SS; Dancourt J; Aaronson J; Rosinski J; Neri C
BMC Bioinformatics; 2020 Feb; 21(1):75. PubMed ID: 32093602
[TBL] [Abstract][Full Text] [Related]
39. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
